Innovative Pharmaceutical Biotech (HK:0399) has released an update.
Innovative Pharmaceutical Biotech Limited has announced the signing of a non-binding Memorandum of Understanding (MOU) with a strategic partner to explore the formation of a joint venture. This venture will focus on the disposable digestive endoscopy market in China, leveraging both companies’ expertise and resources, with the goal of entering into a formal, legally binding agreement by October 31, 2024. Investors are cautioned to exercise prudence when dealing with the company’s shares, as the joint venture’s formation is not guaranteed.
For further insights into HK:0399 stock, check out TipRanks’ Stock Analysis page.
